Evolution Spine, LLC
$263.2K 96 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
IBSA Pharma Inc.
IBSA Pharma Inc. reported $263,410.77 across General Payments, Research, and Ownership to 8,301 physicians and teaching hospitals across 8,308 transactions.
- $263.4K Above-median payer
- All-tracks total
- 8,308 Top quartile volume
- Transactions
- 8,301 Top quartile reach
- Recipients
- −$48.9K
- General Payments vs PY2023
IBSA Pharma Inc. reported $263,410.77 across all CMS Open Payments tracks (General + Research + Ownership) to 8,301 physicians and teaching hospitals in Program Year 2024 - ranking #917 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $247,007.27, averaging $31.73 per recipient.
How IBSA Pharma Inc.'s $263.4K all-tracks total breaks down
IBSA Pharma Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
51/100
Total payments
F
12/100
Transaction volume
C
70/100
Physician reach
C
73/100
Payment type diversity
D
50/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ibsa-pharma-inc IBSA Pharma Inc.
$263.4K · #917/1,925 · 0.0% industry · PY2024
- TOT $263.4K
- RANK #917
- SHARE 0.0%
- TXN 8,308
- RCP 8,301
- CAT 4
- GEN $247.0K
- ΔGEN −$48.9K
- TOP1 3.7%
- PY 2024
Volume peers
Nearest volume peer: Evolution Spine, LLC ($263.2K)
IBSA Pharma Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
IBSA Pharma Inc.'s CMS-reported General Payments decreased by $48.9K (−16.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: IBSA PHARMA INC.PY2023: IBSA PHARMA INC.PY2024: IBSA Pharma Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $295,875.05
- PY2024
- $247,007.27
What the Data Shows for IBSA Pharma Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For IBSA Pharma Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 4 general-payment categories charted below, "Food and Beverage" is the largest at $183.5K across 8,220 transactions, 74.3% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 4 types of general payments, IBSA Pharma Inc.'s largest category was "Food and Beverage" at $183.5K - 74.3% of General Payments.
IBSA Pharma Inc. reports 4 general-payment categories - the top three are Food and Beverage (74.3%), Consulting Fee (20.4%), and Compensation for Services Other Than Consulting (3.7%). The remaining 1 category make up 1.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How IBSA Pharma Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $183.5K | 8,220 | 74.3% |
| Consulting Fee | $50.3K | 56 | 20.4% |
| Compensation for Services Other Than Consulting | $9.2K | 13 | 3.7% |
| Travel and Lodging | $4.0K | 12 | 1.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $26,444.85 (10.7%) of $247,007.27 in this company's General Payments records across 4,844 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for IBSA Pharma Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Felice L Gersh
$9,257.05 across 12 reported transactions
- 2
Bruce Trippe
$5,367.39 across 4 reported transactions
- 3
Brittany Henderson
$4,481.71 across 9 reported transactions
- 4
Lori Ilyse Gerber
$4,011.14 across 7 reported transactions
- 5
Lee Nathaniel Metchick
$3,327.56 across 12 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
IBSA Pharma Inc. ranks #917 of 1,925 by total payments (top 48% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,779 of 1,838 by HHI (bottom 3% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Boston Scientific Corporation : $61.8M total payments, HHI 45
- ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) : $3.8M total payments, HHI 44
- Greer Laboratories, Inc. : $9.8K total payments, HHI 43
- Benco Dental Supply Co. : $148.4K total payments, HHI 43
- Premier Dental Products Company : $182.7K total payments, HHI 43
- DePuy Synthes Sales Inc. : $2.4M total payments, HHI 42
- IBSA Pharma Inc. (this company) : $247.0K total payments, HHI 42
- Supernus Pharmaceuticals, Inc. : $4.4M total payments, HHI 42
- Ethicon US, LLC : $1.6M total payments, HHI 41
- Pylant Medical : $104.7K total payments, HHI 40
- Teva Pharmaceuticals USA, Inc. : $13.9M total payments, HHI 40
- American Orthodontics Corporation : $374.7K total payments, HHI 38
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as IBSA Pharma Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about IBSA Pharma Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with IBSA Pharma Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
THD America, Inc.
$263.2K 501 recipients
Compare payment profiles
J. Morita USA, Inc.
$263.2K 94 recipients
Compare payment profiles
Sterilmed, Inc.
$263.8K 260 recipients
Compare payment profiles
Creo Medical Inc.
$263.8K 276 recipients
Compare payment profiles
Endomagnetics Ltd
$263.0K 1,023 recipients
Compare payment profiles
Put this to use
IBSA Pharma Inc. ranks #917 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just IBSA Pharma Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.